Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2014 from OUS - Department of Molecular Oncology (2006-2014 Dept of Cancer Prev.)

25 publications found

Almeida M, Costa VL, Costa NR, Ramalho-Carvalho J, Baptista T, Ribeiro FR, Paulo P, Teixeira MR, Oliveira J, Lothe RA, Lind GE, Henrique R, Jerónimo C (2014)
Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential
J Cell Mol Med, 18 (11), 2287-97
DOI 10.1111/jcmm.12394, PubMed 25211630

Andreassen OA, Zuber V, Thompson WK, Schork AJ, Bettella F, PRACTICAL Consortium, CRUK GWAS, Djurovic S, Desikan RS, Mills IG, Dale AM (2014)
Shared common variants in prostate cancer and blood lipids
Int J Epidemiol, 43 (4), 1205-14
DOI 10.1093/ije/dyu090, PubMed 24786909

Barfeld SJ, East P, Zuber V, Mills IG (2014)
Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes
BMC Med Genomics, 7, 513
DOI 10.1186/s12920-014-0074-9, PubMed 25551447

Barfeld SJ, Itkonen HM, Urbanucci A, Mills IG (2014)
Androgen-regulated metabolism and biosynthesis in prostate cancer
Endocr Relat Cancer, 21 (4), T57-66
DOI 10.1530/ERC-13-0515, PubMed 24497572

Bethge N, Honne H, Andresen K, Hilden V, Trøen G, Liestøl K, Holte H, Delabie J, Lind GE, Smeland EB (2014)
A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma
PLoS One, 9 (9), e104249
DOI 10.1371/journal.pone.0104249, PubMed 25226156

Bon H, Wadhwa K, Schreiner A, Osborne M, Carroll T, Ramos-Montoya A, Ross-Adams H, Visser M, Hoffmann R, Ahmed AA, Neal DE, Mills IG (2014)
Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer
Mol Cancer Res, 13 (4), 620-635
DOI 10.1158/1541-7786.MCR-13-0182-T, PubMed 25548099

Bruun J, Kolberg M, Nesland JM, Svindland A, Nesbakken A, Lothe RA (2014)
Prognostic Significance of β-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series
Front Oncol, 4, 118
DOI 10.3389/fonc.2014.00118, PubMed 24904831

Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA (2014)
Portrait of the PI3K/AKT pathway in colorectal cancer
Biochim Biophys Acta, 1855 (1), 104-21
DOI 10.1016/j.bbcan.2014.09.008, PubMed 25450577

Danielsen SA, Lind GE, Kolberg M, Høland M, Bjerkehagen B, Sundby Hall K, van den Berg E, Mertens F, Smeland S, Picci P, Lothe RA (2014)
Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis
Neuro Oncol, 17 (1), 63-9
DOI 10.1093/neuonc/nou140, PubMed 25038505

Engedal N, Mills IG (2014)
Endosomal signaling and oncogenesis
Methods Enzymol, 535, 179-200
DOI 10.1016/B978-0-12-397925-4.00012-2, PubMed 24377925

Hveem TS, Merok MA, Pretorius ME, Novelli M, Bævre MS, Sjo OH, Clinch N, Liestøl K, Svindland A, Lothe RA, Nesbakken A, Danielsen HE (2014)
Prognostic impact of genomic instability in colorectal cancer
Br J Cancer, 110 (8), 2159-64
DOI 10.1038/bjc.2014.133, PubMed 24642618

Itkonen HM, Engedal N, Babaie E, Luhr M, Guldvik IJ, Minner S, Hohloch J, Tsourlakis MC, Schlomm T, Mills IG (2014)
UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation
Oncogene, 34 (28), 3744-50
DOI 10.1038/onc.2014.307, PubMed 25241896

Løvf M, Nome T, Bruun J, Eknaes M, Bakken AC, Mpindi JP, Kilpinen S, Rognum TO, Nesbakken A, Kallioniemi O, Lothe RA, Skotheim RI (2014)
A novel transcript, VNN1-AB, as a biomarker for colorectal cancer
Int J Cancer, 135 (9), 2077-84
DOI 10.1002/ijc.28855, PubMed 24687856

Mills IG (2014)
Maintaining and reprogramming genomic androgen receptor activity in prostate cancer
Nat Rev Cancer, 14 (3), 187-98
DOI 10.1038/nrc3678, PubMed 24561445

Nome T, Hoff AM, Bakken AC, Rognum TO, Nesbakken A, Skotheim RI (2014)
High frequency of fusion transcripts involving TCF7L2 in colorectal cancer: novel fusion partner and splice variants
PLoS One, 9 (3), e91264
DOI 10.1371/journal.pone.0091264, PubMed 24608966

Oppelt A, Haugsten EM, Zech T, Danielsen HE, Sveen A, Lobert VH, Skotheim RI, Wesche J (2014)
PIKfyve, MTMR3 and their product PtdIns5P regulate cancer cell migration and invasion through activation of Rac1
Biochem J, 461 (3), 383-90
DOI 10.1042/BJ20140132, PubMed 24840251

Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon H, Theodorou V, Vias M, Shaw GL, Sharma NL, Ross-Adams H, Scott HE, Vowler SL, Howat WJ, Warren AY, Wooster RF, Mills IG, Neal DE (2014)
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network
EMBO Mol Med, 6 (5), 651-61
DOI 10.1002/emmm.201303581, PubMed 24737870

Sharma NL, Massie CE, Butter F, Mann M, Bon H, Ramos-Montoya A, Menon S, Stark R, Lamb AD, Scott HE, Warren AY, Neal DE, Mills IG (2014)
The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer
Nucleic Acids Res, 42 (10), 6256-69
DOI 10.1093/nar/gku281, PubMed 24753418

Sirnes S, Lind GE, Bruun J, Fykerud TA, Mesnil M, Lothe RA, Rivedal E, Kolberg M, Leithe E (2014)
Connexins in colorectal cancer pathogenesis
Int J Cancer, 137 (1), 1-11
DOI 10.1002/ijc.28911, PubMed 24752574

Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F (2014)
Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
Genes Chromosomes Cancer, 53 (7), 558-67
DOI 10.1002/gcc.22166, PubMed 24634323

Sveen A, Johannessen B, Teixeira MR, Lothe RA, Skotheim RI (2014)
Transcriptome instability as a molecular pan-cancer characteristic of carcinomas
BMC Genomics, 15, 672
DOI 10.1186/1471-2164-15-672, PubMed 25109687

Sørlie T, Johnsen H, Vu P, Lind GE, Lothe R, Børresen-Dale AL (2014)
Mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE)
Methods Mol Biol, 1105, 315-24
DOI 10.1007/978-1-62703-739-6_25, PubMed 24623239

Vedeld HM, Andresen K, Eilertsen IA, Nesbakken A, Seruca R, Gladhaug IP, Thiis-Evensen E, Rognum TO, Boberg KM, Lind GE (2014)
The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers
Int J Cancer, 136 (4), 844-53
DOI 10.1002/ijc.29039, PubMed 24948044

Vedeld HM, Skotheim RI, Lothe RA, Lind GE (2014)
The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer
Epigenetics, 9 (3), 346-50
DOI 10.4161/epi.27582, PubMed 24384857

Zecchini V, Madhu B, Russell R, Pértega-Gomes N, Warren A, Gaude E, Borlido J, Stark R, Ireland-Zecchini H, Rao R, Scott H, Boren J, Massie C, Asim M, Brindle K, Griffiths J, Frezza C, Neal DE, Mills IG (2014)
Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer
EMBO J, 33 (12), 1365-82
DOI 10.15252/embj.201386874, PubMed 24837709

 
Page visits: 70970